Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607692 | 0.86 | LOXL2 (0.44) | KCNH2ACVR1ENPP3ENPP1 | |
| SCHEMBL2925165 | 0.84 | MAOB (0.43) | KCNH2ENPP3ENPP1 | |
| Hydrochloric Acid SCHEMBL2926449 | 0.83 | MAOB (0.44) | KCNH2 | |
| SCHEMBL15884572 | 0.81 | RAF1 (0.44) | ACVR1PIK3CA | |
| SCHEMBL3115300 | 0.81 | DYRK1A (0.48) | ACVR1PIK3CA | |
| SCHEMBL2925161 | 0.81 | GRM2 (0.40) | KCNH2ENPP3ENPP1WNT3A | |
| SCHEMBL2919816 | 0.77 | PDE10A (0.49) | ACVR1PIK3CA | |
| SCHEMBL2925641 | 0.75 | GRM2 (0.44) | — | |
| SCHEMBL2925960 | 0.74 | AKT1 (0.42) | — | |
| SCHEMBL13175669 | 0.74 | RPS6KA3 (0.36) | KCNH2ACVR1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | claimed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | claimed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885ACVR1 4835/4885ENPP3 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.